U.S. Markets closed

Sangamo Therapeutics and Three Additional Stocks Under Scanner in the Biotech Space

Stock Research Monitor: RIOT, RXII, and SAGE

LONDON, UK / ACCESSWIRE / June 6, 2018 / If you want a free Stock Review on SGMO sign up now at www.wallstequities.com/registration. On Tuesday, June 05, 2018, the NASDAQ Composite ended the trading session at 7,637.86, up 0.41%; the Dow Jones Industrial Average edged 0.06% lower, to finish at 24,799.98; and the S&P 500 closed at 2,748.80, slightly advancing 0.07%. US markets saw five out of nine sectors finishing the day in red, three in green, and one in neutral territory. This Wednesday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Riot Blockchain Inc. (NASDAQ: RIOT), RXi Pharmaceuticals Corp. (NASDAQ: RXII), Sage Therapeutics Inc. (NASDAQ: SAGE), and Sangamo Therapeutics Inc. (NASDAQ: SGMO).All you have to do is sign up today for this free limited time offer by clicking the link below.


Riot Blockchain

Castle Rock, Colorado-based Riot Blockchain Inc.'s stock finished Tuesday's session 0.91% higher at $7.80 with a total trading volume of 296,284 shares. The Company's shares have advanced 121.43% over the past twelve months. The stock is trading above its 50-day moving average by 6.58%. Additionally, shares of Riot Blockchain, which builds and supports various blockchain technologies, have a Relative Strength Index (RSI) of 53.54. Get the full research report on RIOT for free by clicking below at:


RXi Pharmaceuticals

On Tuesday, shares in Marlborough, Massachusetts headquartered RXi Pharmaceuticals Corp. recorded a trading volume of 164,075 shares. The stock ended the session 5.44% higher at $2.52. The Company's shares have advanced 2.44% in the last month. The stock is trading below its 50-day moving average by 6.42%. Moreover, shares of RXi Pharma, which focuses on discovering and developing immuno-oncology therapeutics to treat cancer, have an RSI of 51.59. Get access to our top-rated research, including the free report on RXII at:


Sage Therapeutics

Cambridge, Massachusetts headquartered Sage Therapeutics Inc.'s shares closed the day 1.36% lower at $154.09. The stock recorded a trading volume of 315,095 shares. The Company's shares have gained 121.17% over the last twelve months. The stock is trading above its 200-day moving average by 19.31%. Additionally, shares of Sage Therapeutics, which develops and commercializes novel medicines to treat central nervous system disorders, have an RSI of 48.19. Click here to subscribe for a free membership which welcomes you with our report on SAGE at:


Sangamo Therapeutics

Shares in Richmond, California headquartered Sangamo Therapeutics Inc. finished 3.40% higher at $16.75. The stock recorded a trading volume of 2.88 million shares, which is above its three months average volume of 2.37 million shares. The Company's shares have advanced 132.64% over the last twelve months. The stock is trading below its 50-day moving average by 3.07%. Furthermore, shares of Sangamo Therapeutics, which focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy, have an RSI of 55.01. Join our big investor community at Wall St. Equities today and get your free report on SGMO at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities